CLIME-CJD: A Multimodal Study

N/AEnrolling By InvitationNCT07589283

First Affiliated Hospital of Fujian Medical University150 enrolled

Overview

Creutzfeldt-Jakob disease (CJD) is a rare and rapidly progressive neurological disorder. This study aims to describe and summarize the key features of CJD by looking back at medical records of patients who were diagnosed with CJD at our hospital. The researchers will collect information from routine clinical evaluations, including patients' symptoms, blood tests, cerebrospinal fluid analysis, brain imaging (such as MRI and PET), and electroencephalography (EEG). By analyzing these data together, the study hopes to provide a clearer picture of how CJD presents in routine clinical practice. This may help doctors recognize the disease more quickly in the future. No new tests or treatments will be given to patients. All data are collected from existing medical records.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Creutzfeldt-Jakob Disease (CJD) | Prion Disease

Interventions

No InterventionsOTHER

No Interventions

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of definite or probable Creutzfeldt-Jakob Disease (CJD) according to the established WHO diagnostic criteria * Available medical records covering at least one of the following: clinical history, peripheral blood test results, cerebrospinal fluid (CSF) analysis findings, brain MRI reports/images, or EEG reports * Hospitalized or evaluated at the participating institution during the study period Exclusion Criteria: * Alternative diagnosis confirmed that explains all clinical features (e.g., autoimmune encephalitis, rapidly progressive dementia due to other causes) * Incomplete medical records with no relevant clinical, laboratory, imaging, or EEG data available * Patient or legal representative declined the use of medical records for research purposes (where applicable according to local regulations)

Outcomes

Primary Outcomes

Proportion of CJD Patients With Characteristic Diagnostic Findings

The primary outcome is the proportion of patients showing characteristic abnormalities across five domains: clinical symptoms, peripheral blood markers, cerebrospinal fluid 14-3-3 protein and RT-QuIC, brain MRI (cortical ribboning or basal ganglia hyperintensity), and EEG (periodic sharp wave complexes).

Time frame: Baseline